Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach
Abstract Background Gene fusions exist with low prevalence in colorectal cancer (CRC), and the clinical utility of fusion testing in advanced CRC remains unclear. We sought to identify oncogenic fusions in patients with advanced CRC using a fusion partner-agnostic circulating tumor DNA (ctDNA) assay...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14117-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333428731772928 |
|---|---|
| author | Andrew J. Pellatt Reagan M. Barnett Sante Gnerre Kristin Edwards Jason A. Willis Michael J. Overmann Kanwal Raghav Christine M. Parseghian Arvind Dasari M. Pia Morelli Alisha Bent Madhulika Eluri Nicholas Hornstein Leylah M. Drusbosky Scott Kopetz Van K. Morris |
| author_facet | Andrew J. Pellatt Reagan M. Barnett Sante Gnerre Kristin Edwards Jason A. Willis Michael J. Overmann Kanwal Raghav Christine M. Parseghian Arvind Dasari M. Pia Morelli Alisha Bent Madhulika Eluri Nicholas Hornstein Leylah M. Drusbosky Scott Kopetz Van K. Morris |
| author_sort | Andrew J. Pellatt |
| collection | DOAJ |
| description | Abstract Background Gene fusions exist with low prevalence in colorectal cancer (CRC), and the clinical utility of fusion testing in advanced CRC remains unclear. We sought to identify oncogenic fusions in patients with advanced CRC using a fusion partner-agnostic circulating tumor DNA (ctDNA) assay to better understand their clinical relevance. Methods We performed a retrospective analysis using de-identified data from 18,558 patients with advanced CRC who underwent ctDNA next-generation sequencing with Guardant360® from 2017 to 2022. These samples were subsequently reanalyzed with a partner-agnostic bioinformatics method to identify both clonal and non-clonal fusions. We analyzed for associations between fusions and MSI-H status, as well prior EGFR-directed therapy signature. Results Fusions were identified in 221 (1.3%) of CRC patients analyzed. 193 patients had 258 activating fusions, while 28 patients had fusions of uncertain significance. Among patients with activating fusions, there were 18 clonal fusions (7%) and 240 (93%) subclonal fusions. Clonal fusions were more common in patients with MSI-H status, and subclonal fusions were associated with prior EGFR exposure signature. Conclusions Among patients with advanced CRC, partner-agnostic ctDNA fusion detection is possible and improves identification as a blood-based approach by extension of fusion calling partners. Detection of fusions in the ctDNA may provide rationale for potential therapeutic strategies according to clonality as informed by the ctDNA, whereas subclonal fusions may play a role in acquired resistance to EGFR inhibitors in KRAS/NRAS/BRAF wild−type tumors. |
| format | Article |
| id | doaj-art-1c69a8a7b2d54f558087ae07e6e2fdc7 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-1c69a8a7b2d54f558087ae07e6e2fdc72025-08-20T03:45:52ZengBMCBMC Cancer1471-24072025-07-0125111010.1186/s12885-025-14117-9Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approachAndrew J. Pellatt0Reagan M. Barnett1Sante Gnerre2Kristin Edwards3Jason A. Willis4Michael J. Overmann5Kanwal Raghav6Christine M. Parseghian7Arvind Dasari8M. Pia Morelli9Alisha Bent10Madhulika Eluri11Nicholas HornsteinLeylah M. Drusbosky12Scott Kopetz13Van K. Morris14Intermountain HealthGuardant Health, Inc.Guardant Health, Inc.Guardant Health, Inc.University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterGuardant Health, Inc.University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterAbstract Background Gene fusions exist with low prevalence in colorectal cancer (CRC), and the clinical utility of fusion testing in advanced CRC remains unclear. We sought to identify oncogenic fusions in patients with advanced CRC using a fusion partner-agnostic circulating tumor DNA (ctDNA) assay to better understand their clinical relevance. Methods We performed a retrospective analysis using de-identified data from 18,558 patients with advanced CRC who underwent ctDNA next-generation sequencing with Guardant360® from 2017 to 2022. These samples were subsequently reanalyzed with a partner-agnostic bioinformatics method to identify both clonal and non-clonal fusions. We analyzed for associations between fusions and MSI-H status, as well prior EGFR-directed therapy signature. Results Fusions were identified in 221 (1.3%) of CRC patients analyzed. 193 patients had 258 activating fusions, while 28 patients had fusions of uncertain significance. Among patients with activating fusions, there were 18 clonal fusions (7%) and 240 (93%) subclonal fusions. Clonal fusions were more common in patients with MSI-H status, and subclonal fusions were associated with prior EGFR exposure signature. Conclusions Among patients with advanced CRC, partner-agnostic ctDNA fusion detection is possible and improves identification as a blood-based approach by extension of fusion calling partners. Detection of fusions in the ctDNA may provide rationale for potential therapeutic strategies according to clonality as informed by the ctDNA, whereas subclonal fusions may play a role in acquired resistance to EGFR inhibitors in KRAS/NRAS/BRAF wild−type tumors.https://doi.org/10.1186/s12885-025-14117-9Colorectal cancerFusionEGFRctDNA |
| spellingShingle | Andrew J. Pellatt Reagan M. Barnett Sante Gnerre Kristin Edwards Jason A. Willis Michael J. Overmann Kanwal Raghav Christine M. Parseghian Arvind Dasari M. Pia Morelli Alisha Bent Madhulika Eluri Nicholas Hornstein Leylah M. Drusbosky Scott Kopetz Van K. Morris Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach BMC Cancer Colorectal cancer Fusion EGFR ctDNA |
| title | Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach |
| title_full | Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach |
| title_fullStr | Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach |
| title_full_unstemmed | Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach |
| title_short | Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach |
| title_sort | detection of oncogenic fusions in colorectal cancer using a partner agnostic next generation sequencing approach |
| topic | Colorectal cancer Fusion EGFR ctDNA |
| url | https://doi.org/10.1186/s12885-025-14117-9 |
| work_keys_str_mv | AT andrewjpellatt detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT reaganmbarnett detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT santegnerre detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT kristinedwards detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT jasonawillis detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT michaeljovermann detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT kanwalraghav detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT christinemparseghian detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT arvinddasari detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT mpiamorelli detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT alishabent detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT madhulikaeluri detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT nicholashornstein detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT leylahmdrusbosky detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT scottkopetz detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach AT vankmorris detectionofoncogenicfusionsincolorectalcancerusingapartneragnosticnextgenerationsequencingapproach |